Table 2.
Prognostic factors for overall survival and Progress-free survival before PSM.
| Clinical variables | Overall survival | Progress-free survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Treatment allocation, LR vs. TACE | 0.429 (0.288–0.637) | <0.001 | 0.520 (0.331–0.815) | 0.004 | 0.614 (0.421–0.897) | 0.012 | 0.618 (0.420–0.909) | 0.015 |
| Age (per 1 year increase) | 0.993 (0.975–1.012) | 0.490 | 0.990 (0.973–1.007) | 0.256 | ||||
| Sex, male vs. female | 1.204 (0.766–1.892) | 0.421 | 1.099 (0.712–1.694) | 0.670 | ||||
| Child–Pugh class, B vs. A | 1.588 (1.101–2.292) | 0.013 | 1.357 (0.950–1.939) | 0.093 | ||||
| HBsAg, positive vs. negative | 1.411 (0.965–2.063) | 0.076 | 1.385 (0.960–1.996) | 0.081 | ||||
| HBeAg, positive vs. negative | 1.122 (0.630–1.998) | 0.696 | 1.287 (0.723–2.290) | 0.392 | ||||
| Anti-HCV, positive vs. negative | 1.030 (0.379–2.793) | 0.954 | 1.907 (0.606–6.002) | 0.270 | ||||
| HBV DNA, >1,000 vs. ≤1,000 copies/ml | 1.104 (0.722–1.689) | 0.648 | 1.009 (0.663–1.537) | 0.966 | ||||
| WBC (per 1 ∗ 109/L increase) | 1.047 (0.964–1.137) | 0.273 | 1.037 (0.957–1.123) | 0.347 | ||||
| HGB (per 1 g/L increase) | 0.985 (0.972–0.997) | 0.015 | 0.985 (0.973–0.999) | 0.029 | 0.992 (0.980–1.004) | 0.186 | ||
| PLT (per 1 ∗ 109/L increase) | 0.999 (0.997–1.002) | 0.635 | 1.000 (0.998–1.002) | 0.827 | ||||
| ALB (per 1 g/L increase) | 0.958 (0.935–0.981) | <0.001 | 0.967 (0.936–1.000) | 0.049 | 0.973 (0.949–0.997) | 0.028 | ||
| TBIL (per 1 umol/L increase) | 1.002 (1.000–1.003) | 0.055 | 1.002 (1.000–1.003) | 0.027 | 1.003 (1.001–1.004) | 0.004 | ||
| ALT (per 1 U/L increase) | 0.998 (0.995–1.001) | 0.118 | 0.999 (0.996–1.001) | 0.237 | ||||
| GGT (per 1 U/L increase) | 1.000 (0.999–1.000) | 0.912 | 1.000 (1.000–1.000) | 0.924 | ||||
| ALP (per 1 U/L increase) | 1.000 (0.999–1.002) | 0.495 | 1.000 (0.999–1.001) | 0.552 | ||||
| PT (per 1 s increase) | 1.090 (0.978–1.215) | 0.120 | 1.059 (0.953–1.177) | 0.283 | ||||
| Scr (per 1 umol/L increase) | 0.990 (0.975–1.004) | 0.165 | 0.995 (0.981–1.009) | 0.491 | ||||
| CA 19-9 (per 1 U/ml increase) | 1.001 (1.000–1.001) | 0.105 | 1.000 (1.000–1.001) | 0.172 | ||||
| AFP, >400 vs. ≤400 ng/ml | 1.168 (0.788–1.730) | 0.439 | 1.147 (0.788-1.668) | 0.475 | ||||
| Tumor diameter, >5 vs. ≤5 cm | 1.069 (0.746–1.532) | 0.715 | 1.039 (0.735–1.468) | 0.829 | ||||
| Tumor number, multiple vs. solitary | 2.066 (1.354–3.154) | 0.001 | 1.982 (1.247–3.152) | 0.004 | 1.545 (1.022–2.336) | 0.039 | 1.625 (1.053–2.507) | 0.028 |
| Major vascular invasion, yes vs. no | 1.797 (1.021–3.161) | 0.042 | 1.429 (0.819–2.493) | 0.209 | ||||
HCC, hepatocellular carcinoma; BDTT, bile duct tumor thrombus; TACE, transarterial chemoembolization; CM, conservative management; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HCV, hepatitis C virus; HBV DNA; hepatitis B virus deoxyribonucleic acid; WBC, white blood cell; HGB, hemoglobin; PLT, platelet; ALB, albumin; TBIL, total bilirubin; ALT, alanine aminotransferase; GGT, γ-glutamyltransferase; ALP, alkaline phosphatase; PT, prothrombin time; Scr, serum creatinine; CA19-9, carbohydrate antigen 19-9; AFP, α-fetoprotein.
Statistically significant values are depicted as bold format.